{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-162755","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.359765+00:00","generated_at":"2026-05-15T05:23:26.259319+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kyverna Phase 2 miv-cel data shows 100% response rate at 24 weeks in gMG; durable to 52 weeks","bullets":["100% of 7 patients achieved ≥3-point reduction in MG-ADL and QMG (co-primary endpoints) at 24 weeks; mean reductions -8.5 and -11.3 points.","57% of patients achieved minimal symptom expression (MG-ADL 0 or 1) at last follow-up; responses deepened over time.","100% were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn/complement inhibitors through Week 24.","No high-grade CRS or ICANS; two transient grade 3/4 neutropenia events resolved; safety supports outpatient administration.","Median follow-up 10.2 months (range 3.3–16.0); company enrolling Phase 3 registrational trial across 14 sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-162755","json":"https://secwatch.observer/filing/0001193125-26-162755.json","markdown":"https://secwatch.observer/filing/0001193125-26-162755.md","text":"https://secwatch.observer/filing/0001193125-26-162755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526162755/0001193125-26-162755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526162755/kytx-20260420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:23:26.259319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}